• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BetterInvesting™ Magazine Update on Vertiv Holdings Co. (NYSE: VRT) and CVS Health Corp. (NYSE: CVS)

    9/30/25 10:20:00 AM ET
    $CVS
    $VRT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Industrial Machinery/Components
    Technology
    Get the next $CVS alert in real time by email

    TROY, Mich., Sept. 30, 2025 /PRNewswire/ -- Vertiv Holdings Co.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine consider Vertiv Holdings Co. (NYSE:VRT) as worthy of further study and has named the company its "Stock to Study" for the December 2025 issue for investors' informational and educational use.

    The fundamental data is eye-opening; investors can view Vertiv's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/study/ssgplus/?studyid=17125916.

    A full report on Vertiv will appear in the December 2025 issue of BetterInvesting Magazine. 

    The same issue of BetterInvesting Magazine will also include a fundamental review of CVS Health Corp. (NYSE:CVS), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. 

    Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    Doron P. Levin, an editor of the magazine, serves as the committee's chairperson.

    Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn, Instagram and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-vertiv-holdings-co-nyse-vrt-and-cvs-health-corp-nyse-cvs-302571020.html

    SOURCE National Association of Investors/BetterInvesting

    Get the next $CVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVS
    $VRT

    CompanyDatePrice TargetRatingAnalyst
    CVS Health Corporation
    $CVS
    10/14/2025$91.00Buy
    Goldman
    Vertiv Holdings LLC
    $VRT
    8/20/2025$135.00Neutral
    Rothschild & Co Redburn
    CVS Health Corporation
    $CVS
    8/18/2025$79.00Neutral → Buy
    UBS
    CVS Health Corporation
    $CVS
    8/14/2025$82.00Neutral → Outperform
    Robert W. Baird
    Vertiv Holdings LLC
    $VRT
    7/28/2025Outperform
    William Blair
    Vertiv Holdings LLC
    $VRT
    7/8/2025$165.00Hold → Buy
    Melius
    Vertiv Holdings LLC
    $VRT
    4/8/2025$75.00Buy
    ROTH MKM
    Vertiv Holdings LLC
    $VRT
    3/7/2025$121.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $CVS
    $VRT
    SEC Filings

    View All

    Vertiv Holdings LLC filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vertiv Holdings Co (0001674101) (Filer)

    12/5/25 6:29:52 AM ET
    $VRT
    Industrial Machinery/Components
    Technology

    SEC Form 8-K filed by CVS Health Corporation

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    11/20/25 4:18:11 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Vertiv Holdings LLC filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vertiv Holdings Co (0001674101) (Filer)

    11/14/25 6:32:50 AM ET
    $VRT
    Industrial Machinery/Components
    Technology

    $CVS
    $VRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Mahoney Michael F bought $2,001,000 worth of shares (30,000 units at $66.70), increasing direct ownership by 321% to 39,356 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    2/19/25 12:35:35 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $VRT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVS Health generates over $474 Billion in 2024 U.S. economic impact, supporting communities throughout the United States

    New report highlights the company's role as a top U.S. employer, investing in improving health and supporting local communities WOONSOCKET, R.I., Dec. 5, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) today released its inaugural National Economic Impact Report demonstrating the positive economic impact that the company has in communities across the country. The report demonstrates how CVS Health delivers $474 billion annually for the U.S. economy and supports 1.3 million jobs nationwide through its operations in every U.S. state and Washington, D.C. In addition, CVS Health oper

    12/5/25 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Vertiv Completes Acquisition of PurgeRite, Expanding Leadership in Liquid Cooling Services

    ~$1.0 billion purchase strengthens Vertiv's capabilities in specialized fluid management services for high-density computing and AI applications COLUMBUS, Ohio, Dec. 4, 2025 /PRNewswire/ -- Vertiv Holdings Co (NYSE:VRT), a global provider of critical digital infrastructure, today announced the successful completion of its previously reported intent to acquire Purge Rite Intermediate LLC ("PurgeRite"), a leading provider of mechanical flushing, purging and filtration services for data centers and other mission-critical facilities. The approximately $1.0 billion acquisition enhances Vertiv's thermal management services capabilities and strengthens its position as a global leader in next-genera

    12/4/25 7:04:00 PM ET
    $VRT
    Industrial Machinery/Components
    Technology

    Aetna expands initiatives to simplify experiences for health care professionals and patients

    Bundling medical procedures and pharmaceutical medications into one prior authorizationImplementing end-to-end generative AI capabilities into Aetna Health appHARTFORD, Conn., Dec. 4, 2025 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE:CVS), today announces key milestones in support of the company's comprehensive strategy announced in June to remove friction in the healthcare system and improve the experience for healthcare professionals and their patients.   "Aetna committed to several bold actions earlier this year that were intended to improve the American healthcare industry and I'm proud of the progress we've made against these commitments," said Aetna p

    12/4/25 8:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $VRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on CVS Health with a new price target

    Goldman initiated coverage of CVS Health with a rating of Buy and set a new price target of $91.00

    10/14/25 8:48:20 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Rothschild & Co Redburn initiated coverage on Vertiv with a new price target

    Rothschild & Co Redburn initiated coverage of Vertiv with a rating of Neutral and set a new price target of $135.00

    8/20/25 9:03:10 AM ET
    $VRT
    Industrial Machinery/Components
    Technology

    CVS Health upgraded by UBS with a new price target

    UBS upgraded CVS Health from Neutral to Buy and set a new price target of $79.00

    8/18/25 8:45:28 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $VRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Cont & Chief Acct Officer Clark James David covered exercise/tax liability with 220 shares, decreasing direct ownership by 0.89% to 24,401 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    12/2/25 6:03:33 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP, Chief Exp & Tech Officer Mandadi Tilak covered exercise/tax liability with 6,575 shares, decreasing direct ownership by 8% to 74,085 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    12/2/25 5:52:02 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Farah Roger N covered exercise/tax liability with 9,748 shares, decreasing direct ownership by 33% to 19,438 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    12/2/25 5:50:02 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $VRT
    Leadership Updates

    Live Leadership Updates

    View All

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Vertiv Announces Leadership Transition in EMEA Region

    Paul Ryan named as president, Europe, Middle East and Africa as of January 1, 2026 COLUMBUS, Ohio, Oct. 13, 2025 /PRNewswire/ -- Vertiv (NYSE:VRT), a global leader in critical digital infrastructure, today announced that Karsten Winther will retire from his position as president, Europe, Middle East and Africa (EMEA), effective December 31, 2025. Paul Ryan, currently chief procurement officer, has been appointed as his successor, starting January 1, 2026. "Karsten has made impactful contributions to Vertiv during his tenure, particularly in strengthening our EMEA region throug

    10/13/25 10:45:00 AM ET
    $VRT
    Industrial Machinery/Components
    Technology

    Vertiv Names Craig Chamberlin as Chief Financial Officer

    COLUMBUS, Ohio, Oct. 13, 2025 /PRNewswire/ -- Vertiv Holdings Co (NYSE:VRT), a global leader in critical digital infrastructure, today announced the appointment of Craig Chamberlin as Executive Vice President and Chief Financial Officer, effective November 10, 2025. Mr. Chamberlin succeeds David Fallon, who previously announced his intention to retire from Vertiv and serve as a consultant to the company through December 31, 2026. Mr. Chamberlin joins Vertiv from Wabtec Corporation, where he most recently served as Group Vice President and Chief Financial Officer of the company

    10/13/25 6:45:00 AM ET
    $VRT
    Industrial Machinery/Components
    Technology

    $CVS
    $VRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Vertiv Holdings LLC

    SC 13G - Vertiv Holdings Co (0001674101) (Subject)

    11/13/24 4:34:55 PM ET
    $VRT
    Industrial Machinery/Components
    Technology

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by Vertiv Holdings LLC

    SC 13G/A - Vertiv Holdings Co (0001674101) (Subject)

    11/12/24 5:49:48 PM ET
    $VRT
    Industrial Machinery/Components
    Technology

    $CVS
    $VRT
    Financials

    Live finance-specific insights

    View All

    Vertiv Declares Quarterly Dividend

    COLUMBUS, Ohio, Nov. 14, 2025 /PRNewswire/ -- Vertiv Holdings Co (NYSE:VRT), a global leader in critical digital infrastructure, today announced that its Board of Directors has raised its regular annual cash dividend by 67% from $0.15 to $0.25 per share, to be declared and paid quarterly, reflecting the company's strong financial performance and cash flow. The increase will be effective starting with the fourth-quarter cash dividend of $0.0625 per share of Class A common stock, which was declared by the Board of Directors November 13, 2025, and is payable on December 18, 2025, to shareholders of record of Class A common stock at the close of business on November 25, 2025.

    11/14/25 6:30:00 AM ET
    $VRT
    Industrial Machinery/Components
    Technology

    CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

    Financial Highlights Third quarter total revenues increased to a record high $102.9 billion, up 7.8% compared to prior yearThird quarter GAAP diluted loss per share of $3.13, inclusive of a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unitThird quarter Adjusted EPS of $1.60Generated year-to-date cash flow from operations of $7.2 billionOperational Highlights Aetna® receives industry-leading Medicare Advantage Star Ratings resultsLaunch of annual vaccination campaign at CVS Pharmacy® and MinuteClinic® locations nationwideCaremark® closes out another strong selling season with contract wins totaling nearly $6.0 billion and retention in the high nineties

    10/29/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Vertiv Reports Strong Third Quarter Results including Organic Orders +60%, Diluted EPS +122% (Adjusted EPS +63%); Raises 2025 Guidance

    Third quarter organic orders up ~60% compared to prior year period and up 20% sequentially from second quarter 2025. Strong third quarter trailing twelve-month (TTM) organic orders up 21% compared to prior year TTM period.Diluted EPS of $1.02 and adjusted diluted EPS(1) of $1.24, up 63% from third quarter 2024Third quarter net sales up 29% and organic net sales(1) up 28% compared to prior year third quarterOperating profit of $517 million, up 39% from third quarter 2024, and adjusted operating profit(1) of $596 million, up 43% from third quarter 2024Adjusted operating margin of 22.3%, up 220 basis points compared to third quarter 2024 and up 380 basis points sequentially from second quarter

    10/22/25 5:55:00 AM ET
    $VRT
    Industrial Machinery/Components
    Technology